中文版English

Home | Add to Favorites | Contact Us

Home >> Enterprises >> Beijing Union Pharmaceutical Factory

 

Beijing Union Pharmaceutical Factory and Beijing Union Second Pharmaceutical Factory are subordinate to Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College. The business covers areas of medical R&D, production and marketing. We have been listed as new & high-tech enterprises and were incorporated into the scope of central state-owned capital management budget implementation in 2012.
The manufacturing bases are equipped with advanced production lines for bulk drug, tablets, capsules, pilules, creams, small volume injections (including anti-tumor class) and freeze-dried powder injections (antineoplastic agents) which have passed GMP inspection.
With the strong innovation resources that are available to us and scientific supports from IMM, we are able to focus on the creation and production of innovative drugs with proprietary intellectual property rights useful in treating or preventing serious diseases. Main pharmaceutical products include the innovative anti-hepatitis drug Bicyclol Tablets, which was awarded National Second Prize for Progress in Science and Technology, antineoplastic paclitaxel injection and cardiovascular drug Felodipine Tablets, which were produced in China for the first time, and Fanghuosu, which is the critical material of artificial musk, etc.
With quality advantages, Bicyclol tablets, Bifendate pills and Ftibamzone cream have been sold domestically and internationally, including Ukraine, Kazakhstan, Uzbekistan, Kyrghizstan, Tadzhikistan, Georgia, Egypt, Republic of Korea, Viet Nam and Myanmar, etc.
As we move into the 12th Five-year Plan period, we will continue to dedicate ourselves to innovation and product development, and to maintain positive and steady operation. We will build the state-of-art manufacturing plant of Beijing Union Pharmaceutical Factory and Beijing Union Second Pharmaceutical Factory to enhance our production capacity, and integrate the industry-university-research approach to innovation in drug development with IMM in Daxing Biomedical Industry Base of Zhongguancun Science and Technology Park. We will make continuous efforts to fulfill our commitments to achieving "created in China" in pharmaceutical industry.
 
 

【Back】